US2016052999A1PendingUtilityA1

Functional heavy chain antibodies, fragments thereof, library thereof and methods of production thereof

Assignee: VIB VZWPriority: Oct 24, 2001Filed: Jul 24, 2015Published: Feb 25, 2016
Est. expiryOct 24, 2021(expired)· nominal 20-yr term from priority
A61P 37/06A61P 37/08A61P 1/04C07K 2317/22C07K 2317/21C07K 2317/569C07K 2317/622A61K 2039/505A61P 11/06C07K 2319/22C07K 2317/56A61P 11/02C07K 2317/24C07K 16/3007C07K 16/241C07K 16/005C07K 16/18C07K 2317/92
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to functional heavy chain antibodies, functional single domain heavy chain antibodies, functional VH domains, or functional fragments thereof comprising an amino acid which is neither a charged amino acid nor a C at position 45, and comprising an amino acid at position 103 independently chosen from the group consisting of R, G, K, S, Q, L, and P, and optionally an amino acid at position 108 independently chosen from the group consisting of Q, L and R, said positions determined according to the Kabat numbering.

Claims

exact text as granted — not AI-modified
1 .- 19 . (canceled) 
     
     
         20 . An isolated functional immunoglobulin V-domain from the H-chain of a functional heavy chain antibody (VHH) or from the H-chain of a four-chain antibody (VH),
 wherein the immunoglobulin V-domain selectively binds human serum albumin, and   wherein the amino acid at position 103 is arginine (R) or wherein the amino acid at position 103 is replaced with arginine (R), said position determined according to the Kabat numbering.   
     
     
         21 . The isolated functional immunoglobulin V-domain of  claim 20 , wherein the immunoglobulin V-domain is not stabilized by a disulfide bridge formed between CDR3 and either CDR1 or CDR2. 
     
     
         22 . An isolated fusion polypeptide comprising the isolated functional immunoglobulin V-domain of  claim 20 , wherein the polypeptide is a dimer, trimer or multimer. 
     
     
         23 . A pharmaceutical composition comprising the isolated functional immunoglobulin V-domain according to  claim 20 , optionally in combination with a suitable excipient. 
     
     
         24 . A pharmaceutical composition comprising the isolated functional immunoglobulin V-domain according to  claim 21 , optionally in combination with a suitable excipient. 
     
     
         25 . A pharmaceutical composition comprising the isolated fusion polypeptide according to  claim 22 , optionally in combination with a suitable excipient.

Join the waitlist — get patent alerts

Track US2016052999A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.